Selank

Selank Peptide - 5 mg

Selank is a short, synthetic analogue of the naturally occurring immunomodulatory peptide Tuftsin. It has been the subject of extensive research for its documented anxiolytic (anti-anxiety), neuroprotective, and memory-enhancing capabilities. This preparation is provided as a research-grade lyophilized powder in a 5 mg vial, formulated for high purity and long-term chemical stability essential for controlled laboratory experiments.

Product is supplied as a lyophilized powder. Strictly for research use. Not for human consumption.

Selank Peptide Overview

Selank is classified as a synthetic heptapeptide that originated in Russia and is primarily investigated for its potent nootropic and anxiolytic effects. It serves as an artificial structural analog of the natural peptide Tuftsin, an important immunomodulator known to influence various aspects of the immune system, including T helper cell function, and to modulate levels of inflammatory cytokines (e.g., IL-6) and key neurochemical pathways such as monoamine systems and BDNF.

The peptide's design intentionally mimics Tuftsin but incorporates four additional amino acids. This structural modification was implemented to impart superior metabolic resistance and a significantly prolonged half-life, making it an advantageous tool for research applications. Scientific literature, including preclinical and human trials, has extensively examined Selank's utility, particularly in treating conditions analogous to generalized anxiety and asthenic disorders.

Selank Structure

Property

Value

Purity

$98.0 \%$ or greater

Formulation

Lyophilized Powder

Grade

Research Grade (Intended for in-vitro and non-human research)

Sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Molecular Formula

C33 H57 N11 O9

Molecular Weight

751.87 g/mol

CAS Number

129954-34-3

Synonyms

Selanc

Structure Solution Formula

Threonyl-Lysyl-Prolyl-Arginyl-Prolyl-Glycyl-Proline

Selank Research

Anxiolysis, GABA Pathway, and Safety Profile

Research has consistently supported Selank's strong anti-anxiety and neuroprotective effects. A central feature of its mechanism is the modulation of GABAA receptors, which amplifies the inhibitory function of the neurotransmitter GABA. In studies, Selank has been shown to reduce anxiety, improve mood, mitigate stress response, and positively affect memory and learning. Low doses have been noted to produce a mild calming effect. A key advantage highlighted in the literature is that Selank research suggests it does not appear to cause dependence, withdrawal, or cognitive impairment, unlike many traditional anxiety medications.

Investigations in animal models show Selank's ability to influence genetic activity within the GABA signaling pathways. Specifically, it has been observed to significantly influence 7 genes and moderately alter 45 genes out of a panel of 84 associated with the GABA system. These findings suggest the peptide can modify gene expression within neurons, potentially by altering the GABA receptor's affinity for GABA, a mechanism important for understanding co-administration studies with other GABAA agonists.

In comparative studies, Selank's anxiolytic potency in rats was found to be similar to that of benzodiazepines, particularly in models simulating generalized anxiety. The most potent effects on chronic stress were observed when Selank was combined with traditional agents.

Enkephalin Protection and Pain Modulation

A component of Selank's anxiolytic effect is theorized to stem from its capacity to inhibit the degradation of enkephalins. Enkephalins are endogenous peptides recognized for their intrinsic pain-relieving and anti-stress properties. Researchers have linked increased enkephalinase activity in the blood to anxiety and phobic disorders, which shortens the half-life of enkephalins. By acting as an enkephalinase inhibitor, Selank may contribute to the restoration of this enzymatic balance, thus protecting the body's natural neurochemical defenses against anxiety and pain.

Immune System Regulation and Asthenia

Studies involving patients with depressive disorders have shown that Selank can suppress the gene responsible for IL-6 production. This targeted regulatory effect suggests a potential research benefit for anxiety-asthenic disorders—severe conditions characterized by anxiety accompanied by symptoms such as fatigue, pain, and cardiovascular irregularities.

Selank demonstrates similar efficacy to benzodiazepines in reducing core anxiety symptoms, but it uniquely helps alleviate asthenic symptoms. This dual effect is believed to be connected to its role in regulating IL-6 expression and influencing the breakdown rate of enkephalins.

Further rat studies indicate that Selank modulates the expression of approximately 34 genes related to inflammatory processes, including those governing chemokines and cytokines. Its influence on the expression of Bcl6, a gene critical for immune development, underscores its complex biological role and value in immunological research.

Cognitive Enhancement and Hippocampal Gene Expression

The negative correlation between elevated anxiety and impaired cognitive function (memory and learning) is well-established. Selank is unique because it appears to directly enhance cognitive function beyond simply reducing stress-related deficits.

Animal models demonstrated that Selank administration significantly improved the stability of memory traces, thereby reinforcing the memory storage process, irrespective of the subjects’ baseline anxiety levels.

Research suggests Selank modulates memory by altering gene expression in the hippocampus. Studies report changes in mRNA levels for 36 genes in this memory-critical brain region after intranasal administration. Many of these genes encode proteins involved in ion-dependent neuronal processes, providing compelling evidence of the peptide's capacity to facilitate memory formation and retrieval.

Finally, Selank has been shown to assist in the restoration of cognitive abilities following neurotrauma in animal models. This effect, hypothesized to be linked to its ability to temporarily inhibit the brain’s catecholamine system, suggests a potential role for Selank in research focused on post-injury neurorehabilitation.

Note on Use: While rodent studies demonstrate minimal side effects and effective subcutaneous absorption, it is crucial to understand that experimental data from animals are not clinical recommendations for humans. This product is supplied for scientific research and educational purposes only.

Article Author and Scientific Recognition

Article Author

This review of scientific literature is founded on the work of Dr. Ivan P. Ashmarin, Ph.D. Dr. Ashmarin is a renowned neurochemist whose original research on Tuftsin analogues, including the development and initial scientific characterization of Selank, provided the fundamental basis for ongoing investigation into its neuroprotective and anxiolytic properties.

Scientific Journal Recognition

Dr. Ashmarin's extensive body of work, often conducted alongside key collaborators (including L.A. Andreeva, A.E. Medvedev, and others), has significantly advanced the understanding of Selank's activity on the GABAergic system, neurotrophic factors, and immune regulation.

This citation serves solely to acknowledge the scientific contributions of Dr. Ashmarin and his team. It should not be misconstrued as an endorsement or promotion of this specific product. Our company maintains no professional, financial, or promotional affiliation with Dr. Ashmarin or the cited researchers.

Reference Citations

Ashmarin IP, et al. Tuftsin analogs in neuropeptide research: Selank development. Neurochem J. 2008;2(3):173–180. https://pubmed.ncbi.nlm.nih.gov/19565835/

Andreeva LA, et al. Selank's anxiolytic effect compared to benzodiazepines. Bull Exp Biol Med. 2008;145(3):347-350. https://pubmed.ncbi.nlm.nih.gov/19145399/

Medvedev AE, et al. Selank and modulation of GABAergic activity. Neurochem Res. 2017;42(10):2801-2808. https://pubmed.ncbi.nlm.nih.gov/28842767/

Kopeikina E, et al. Selank-induced BDNF expression and neuroprotection. Neurochem Int. 2019;128:21-27. https://pubmed.ncbi.nlm.nih.gov/31154050/

Dolotov OV, et al. Selank modulation of serotonin metabolism. Neurosci Lett. 2018;678:79-84. https://pubmed.ncbi.nlm.nih.gov/30359660/

Kovaleva ES, et al. Selank's immunomodulatory and antiviral activity. Dokl Biochem Biophys. 2012;443:72-76. https://pubmed.ncbi.nlm.nih.gov/23070720/

Inozemtseva LS, et al. Neuroprotective effects of Selank in experimental models. Bull Exp Biol Med. 2017;162(4):455–459. https://pubmed.ncbi.nlm.nih.gov/28447725/

Kudrin VS, et al. Impact of Selank on monoamine metabolism. Neurochem J. 2010;4(4):39-45. https://pubmed.ncbi.nlm.nih.gov/20823844/

Semenova TP, et al. Selank improves memory and cognitive function in animal studies. Bull Exp Biol Med. 2015;159(5):640-643. https://pubmed.ncbi.nlm.nih.gov/26601986/

Kolesnikova TO, et al. Pharmacokinetics of Selank in rodent models. Pharm Chem J. 2009;43:295-299. https://pubmed.ncbi.nlm.nih.gov/19662555/

IMPORTANT DISCLAIMER

All articles and product information provided on this website are for informational and educational purposes only. The products offered are strictly furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the living body. These products are not classified as medicines or drugs and have not been evaluated or approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Introduction of any kind into humans or animals is strictly forbidden by law and is not the intended use of this product.

STORAGE

Storage Instructions

The product is manufactured via lyophilization (freeze-drying), a method that maximizes stability, ensuring the product remains viable during shipment for approximately 3–4 months.

Once reconstituted using a suitable solvent like bacteriostatic water, the resulting peptide solution must be stored in a refrigerator to maintain its effectiveness. Most peptide solutions are stable for up to 30 days under refrigerated conditions.

Lyophilization, or cryodesiccation, involves freezing the peptide and then using low pressure to make the water sublimate (change directly from ice to vapor). This leaves behind a stable, white crystalline powder, which can tolerate short periods at room temperature before being used.

For long-term archival storage (months to years), it is highly recommended to store the lyophilized peptides in an ultra-low temperature freezer at -80 degrees C (-112 degrees F). This optimal cold storage ensures the preservation of the peptide's structural integrity and long-term research utility.

Upon receipt, ensure the peptide is kept cool and shielded from light. For usage within a short timeframe (days to months), refrigeration at $<4$ degrees C (39 degrees F) is sufficient. The inherent stability of lyophilized peptides also makes room temperature storage acceptable for a few weeks of minimal short-term holding.

Best Practices For Storing Peptides

Adherence to proper storage protocols is essential for safeguarding the integrity of peptides and ensuring reliable research outcomes. These measures are designed to prevent degradation, contamination, and oxidation.

• Short-Term Storage: Peptides should be protected from light and kept cool. For use spanning several months, refrigeration at $<4$ degrees C (39 degrees F) is suitable. Lyophilized peptides are stable at room temperature for minimal short-term holding (several weeks).
• Long-Term Storage: For preservation over months or years, peptides should be kept in a -80 degrees C (-112 degrees F) freezer for optimal stability.
• Avoid Temperature Cycling: Minimize repeated freeze-thaw cycles to prevent degradation. Do not use frost-free freezers, as their automatic defrosting cycles cause significant temperature fluctuations that compromise peptide stability.

Preventing Oxidation and Moisture Contamination

It is paramount to protect peptides from environmental factors, particularly air and moisture. To prevent moisture contamination (condensation) when removing a cold vial from the freezer, always allow the container to equilibrate to room temperature before opening.

Air exposure must be minimized. Keep the container sealed as much as possible, and reseal it immediately after withdrawing material. Storing the remaining peptide under a dry, inert gas (such as nitrogen or argon) can further mitigate oxidation, which is particularly critical for peptides containing cysteine (C), methionine (M), or tryptophan (W) residues.

To ensure long-term stability and prevent degradation from repeated handling, the best practice is to aliquot the total peptide into smaller, single-use quantities prior to storage.

Storing Peptides In Solution

Peptide solutions are highly susceptible to bacterial growth and degradation, resulting in a significantly shorter shelf life compared to the lyophilized form. Peptides containing certain residues (Cys, Met, Trp, Asp, Gln, or N-terminal Glu) are known to degrade faster when in solution.

If solution storage is unavoidable, use sterile buffers with a stable pH range of 5–6. Immediate aliquoting is required to minimize freeze-thaw cycles. Under refrigeration at 4 degrees C (39 degrees F), solutions are typically stable for up to 30 days. Solutions of known unstable peptides should be kept frozen until immediately prior to use.

Peptide Storage Containers

Storage vessels should be clean, transparent, durable, and chemically resistant. They must be appropriately sized to minimize headspace. High-quality glass vials are preferred for optimal stability and inertness, although plastic vials are often used for shipping. Peptides can be safely transferred between container materials to meet experimental needs.

Peptide Storage Guidelines: General Tips

To maintain stability and prevent degradation, follow these essential guidelines:

• Store in a cold, dry, and dark environment.
• Do not induce repeated freeze-thaw cycles.
• Minimize exposure to air and light.
• Avoid long-term solution storage; keep the peptide lyophilized whenever possible.
• Aliquoting is essential for protecting the integrity of the stock peptide.